Social networks
1,938Activities
Technologies
Entity types
Location
21 Rue La Noue Bras de Fer, 44200 Nantes, France
Nantes
France
Employees
Scale: 11-50
Estimated: 41
SIREN
814086534Engaged corporates
10Added in Motherbase
11 months ago[Automatic translation follows] - Innovative Solutions & Efficiency for the Patient -
i-SEP is a French Medtech, founded in 2015 in Nantes, specializing in perioperative autotransfusion and blood saving strategy (Patient Blood Management).
i-SEP has developed and patented an innovative technology for separating blood components. Its ambition is to become the first laboratory to market an autotransfusion system capable of recovering both red blood cells and platelets during hemorrhagic surgical procedures, with ergonomic and intuitive equipment.
i-SEP works closely with leading anesthesiologist-resuscitator teams with the mission of improving patient benefit, simplifying the work of practitioners and helping to reduce healthcare costs.
Our innovation brings significant added value compared to currently available solutions, particularly in terms of blood quality.
i-SEP was co-founded by three partners:
Dr. Francis Gadrat, anesthesiologist, Bertrand Chastenet, former business leader and consultant in the pharmaceutical industry, advisor to French foreign trade, and Sylvain Picot, founder of Biom’Up. i-SEP is supported by Atlanpole and a member of the Atlanpole Biotherapies competitiveness cluster.
------
i-SEP is a French medtech, founded in 2015 in Nantes, specialized in perioperative cell salvage and blood saving strategy (Patient Blood Management).
i-SEP has developed and patented an innovative technology for the separation of blood components. Its ambition is to become the first laboratory to market an autotransfusion system capable of recovering both red blood cells and platelets during hemorrhagic surgeries, using equipment that is both ergonomic and intuitive. i-SEP works closely with reference teams of anesthetists-intensivists specialists with the aim of improving patient benefits, simplifying the work of physicians and helping to reduce healthcare costs.
Patient Blood Management, PeriOperative Cell Recovery, Anesthesiology, MedTech, Autotransfusion, and IOCS
- Innovative Solutions & Efficiency for the Patient -
i-SEP est une Medtech française, fondée en 2015 à Nantes, spécialisée dans l’autotransfusion périopératoire et la stratégie d’épargne sanguine (Patient Blood Management).
i-SEP a développé et breveté une technologie innovante de séparation des composants du sang. Son ambition est de devenir le premier laboratoire à commercialiser un système d’autotransfusion capable de récupérer à la fois les globules rouges et les plaquettes lors d’interventions chirurgicales hémorragiques, et ce avec un équipement ergonomique et intuitif.
i-SEP travaille en étroite collaboration avec les équipes d’anesthésistes réanimateurs de référence avec pour missions d’améliorer le bénéfice patient, de simplifier le travail des praticiens et de contribuer à réduire les coûts de santé.
Notre innovation apporte une valeur ajoutée significative par rapport aux solutions disponibles actuellement, notamment en terme de qualité du sang.
i-SEP a été co-fondée par trois associés :
Dr Francis Gadrat, médecin anesthésiste, Bertrand Chastenet, ancien chef d’entreprise et consultant dans l'industrie pharmaceutique, conseiller du commerce extérieur de la France, et Sylvain Picot, fondateur de Biom’Up. i-SEP est accompagnée par Atlanpole et membre du pôle de compétitivité Atlanpole Biothérapies.
------
i-SEP is a French medtech, founded in 2015 in Nantes, specialized in perioperative cell salvage and blood saving strategy (Patient Blood Management).
i-SEP has developed and patented an innovative technology for the separation of blood components. Its ambition is to become the first laboratory to market an autotransfusion system capable of recovering both red blood cells and platelets during hemorrhagic surgeries, using equipment that is both ergonomic and intuitive. i-SEP works closely with reference teams of anesthetists-intensivists specialists with the aim of improving patient benefits, simplifying the work of physicians and helping to reduce healthcare costs.
Patient Blood Management, PeriOperative Cell Recovery, Anesthesiology, MedTech, Autotransfusion, and IOCS
i-SEP is a French Medtech, based in Nantes (Upper Brittany, France) specialized in intraoperative cell salvage (IOCS) and Patient Blood Management (PBM) .i-SEP has developed and patented an innovative technology for the separation of blood components.
Corporate | Type | Tweets | Articles | |
---|---|---|---|---|
Le Journal des Entreprises Media, Newspaper Publishing | Le Journal des Entreprises Media, Newspaper Publishing | Other 27 Oct 2024 | | |
Samoa Architecture and Planning | Samoa Architecture and Planning | Other 12 Jul 2024 | | |
Nantes Métropole Government Administration, French metropolis | Nantes Métropole Government Administration, French metropolis | Other 12 Jul 2024 | | |
Région Pays de la Loire National and local authorities, Government Administration | Région Pays de la Loire National and local authorities, Government Administration | Other 12 Jul 2024 | | |
Chambre de Commerce et d'Industrie de Nantes St-Nazaire Chamber of commerce, Government Administration | Chambre de Commerce et d'Industrie de Nantes St-Nazaire Chamber of commerce, Government Administration | Other 12 Jul 2024 | | |
Atlanpole Business Consulting and Services | Atlanpole Business Consulting and Services | Other 27 Oct 2024 | | |
NEFTYS Finance, Financial Services | NEFTYS Finance, Financial Services | Other 30 Nov 2023 | | |
France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | Other 27 Oct 2024 | | |
Bpifrance Bank, Banking | Bpifrance Bank, Banking | Other 27 Oct 2024 | | |
Atlanpole Biotherapies Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Atlanpole Biotherapies Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Other 27 Oct 2024 | |